Ploumen EH, Buiten RA, Kok MM, et al. - Given that unknown diabetes or prediabetes may be present in patients with coronary disease, researchers examined post-percutaneous coronary intervention (PCI) outcomes for 3 years in patients with silent diabetes, prediabetes, and normoglycemia who had PCI with contemporary drug-eluting stents (DES). All BIO-RESORT trial participants without recognized diabetes were examined via oral glucose tolerance testing (OGTT) and fasting plasma glucose and glycated hemoglobin levels. Among patients without known diabetes, an independent link of abnormal glucose metabolism by OGTT with higher 3-year target vessel failure (TVF) rates post-PCI with contemporary DES were reported. Periprocedural myocardial infarction (MI) and cardiac death were identified as the drivers of this difference. Low rates of TVF, target vessel MI, and target vessel revascularization were evident after the first 48 hr, and these did not vary significantly between metabolic groups.